Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Arthritis Drug Demonstrates Substantial Hair Regrowth in 1,400 Alopecia Patients
3+ day, 10+ hour ago (426+ words) An arthritis drug of all things was recently found in a study to restore up to 100% of hair in patients with severe alopecia. Around 2% of the world population live with alopecia areata, an autoimmune disorder where the human immune system…...
Common Arthritis Drug Helps Restore Hair in Alopecia Areata Patients, Study Finds
3+ week, 4+ day ago (360+ words) A medication commonly used for inflammatory arthritis may offer another option for people with severe alopecia areata. Two Phase III trials found that upadacitinib helped significantly more patients achieve substantial hair regrowth than a placebo. The findings could expand alopecia…...
Are GLP-1s driving demand for hair growth supplements?
1+ mon, 16+ hour ago (1291+ words) Since GLP-1 drugs went mainstream in the early 2020s, there has been increasing attention on the potential side effects, predominantly gastrointestinal disturbances such as nausea, diarrhea and constipation. In the last three years, however, public interest in the association between GLP…...
Bill pushed by Ipswich woman could see insurance cover wigs for alopecia patients
2+ mon, 1+ day ago (667+ words) IPSWICH — A local woman is continuing her three decades-long fight for insurance companies to cover the cost of wigs for Massachusetts residents with alopecia areata. Heidi Bratt, 65, who also has special needs due to brain damage she sustained at birth,…...
Dayspring Pharma's CG2001 Meets Phase II Endpoint in Male Androgenetic Alopecia Trial
3+ mon, 4+ day ago (180+ words) 09 June 2026 | Tuesday | News CG2001 is a topical fixed-dose combination formulation containing minoxidil and finasteride, being evaluated for the treatment of male androgenetic alopecia. The trial consisted of the following treatment arms: CG2001 (5% Minoxidil and 0.075% Finasteride) once daily (QD); CG2001 (5% Minoxidil and 0.1% Finasteride) once…...
Expert Pearls on the Use of the FoLix Laser for Androgenetic Alopecia
4+ mon, 1+ day ago (113+ words) The Dermatology Digest Expert Pearls on the Use of the FoLix Laser for Androgenetic Alopecia With Dr. Jennifer Krejci Jennifer Krejci, MD, a Dermatologist at the Limmer Hair Transplant Center in San Antonio, TX, recently presented new data on FoLix…...
Baricitinib Effective and Safe for Severe Alopecia Areata when Started Early: Study
4+ mon, 4+ day ago (152+ words) Spain: Researchers have found in a real-world prospective study of adults with severe Alopecia Areata that treatment with Baricitinib demonstrated good efficacy and safety over 12 months, particularly when initiated early. In the study, a clinically meaningful response was observed in…...
Minoxidil Bay Announces Launch of Hair Regrowth Solutions for Men and Women in Canada
4+ mon, 2+ week ago (198+ words) Vancouver, BC – April 27, 2026 – Minoxidil Bay, a Canadian hair care brand focused on science-backed regrowth solutions, has officially announced the launch of its expanded product line designed to support healthier hair growth for men and women experiencing thinning hair and hair…...
New Treatment Shows Promising Results in Hair Growth Trial
4+ mon, 2+ week ago (370+ words) More than 50 million men in the U.S. deal with hair loss, but the solutions haven’t kept their promise. Many treatments are inconvenient, inconsistent, or both. That’s why a new pill currently in phase 3 trials is getting attention: it aims to simplify…...
Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss
4+ mon, 2+ week ago (277+ words) VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and all key secondary endpoints with high statistical significance in both active treatment arms evaluating once-daily (QD) and twice-daily (BID) administration of VDPHL01 Rapid and robust hair growth was achieved with VDPHL01 treatment…...